PATH Malaria Vaccine Initiative

New results on world's most clinically advanced malaria vaccine candidate to be reported in NEJM

The PATH Malaria Vaccine Initiative has reported promising results from two studies on the efficacy of RTS,S/AS malaria vaccine candidate. The first study showed the vaccine's efficacy when co-administered with other childhood vaccines, while the second study demonstrated its effectiveness in children aged 5 to 17 months.

SourcePATH Malaria Vaccine Initiative·JournalNew England Journal of Medicine·DateDec 8, 2008

NEJM: 2 new studies show malaria vaccine candidate advancing in Africa

Two new studies published in NEJM confirm the efficacy of RTS,S/AS, a malaria vaccine candidate, in reducing clinical episodes by 53% in children aged 5-17 months. The vaccine also demonstrates favorable safety profiles and can be administered alongside standard infant vaccines, providing an optimal delivery platform.

SourcePATH Malaria Vaccine Initiative·JournalNew England Journal of Medicine·DateDec 8, 2008